ArteraAI Validates Prognostic Model in Advanced Prostate Cancer
ArteraAI will present data demonstrating the successful validation of its prognostic model in advanced prostate cancer.
Read MorePosted by Andy Lundin | Oct 16, 2023 | Prostate |
ArteraAI will present data demonstrating the successful validation of its prognostic model in advanced prostate cancer.
Read MorePosted by Andy Lundin | Oct 11, 2023 | Cancer, Digital Pathology |
CorePlus, a high complexity anatomic pathology laboratory, diagnosed over 10,000 cases using Ibex’s AI-powered cancer diagnostics platform.
Read MorePosted by Andy Lundin | Oct 10, 2023 | Sequencing Systems |
Centogene announced the expansion of MOx, the company’s multiomic diagnostic portfolio, now incorporating transcriptomic analysis.
Read MorePosted by Andy Lundin | Oct 9, 2023 | Prostate |
Researchers developed a patent-pending method and algorithm to predict prostate cancer recurrence in patients treated by radiation therapy.
Read MorePosted by Andy Lundin | Oct 9, 2023 | Sequencing Systems, Unknown Origin & Other Cancer Types |
The new NGS test detects gene fusions, translocations, and rearrangements across 361 genes from FFPE tumor tissue.
Read More